RedHill Biopharma announces launching of Talicia in the UAE

RedHill Biopharma announced the launch of Talicia, or omeprazole magnesium, amoxicillin and rifabutin, in the United Arab Emirates, or UAE, – making it available by prescription to treat adults with Helicobacter pylori infection. The commercial launch of Talicia in the UAE triggers RedHill’s eligibility for additional potential milestone payments, minimum sales payments and tiered royalties up to mid-teens on net sales. Talicia is the first approved low-dose rifabutin-containing all-in-one combination product in the UAE specifically designed to treat H. pylori. Clarithromycin-based triple therapy continues to wane in effectiveness. A 2021 study demonstrated only 68.5% eradication with traditional clarithromycin-based triple therapy, which declined further to 32% in patients harboring resistant H. pylori organisms. Clarithromycin-based treatment efficacy can also be negatively impacted by patient obesity or diabetic status, neither of which impact Talicia’s safety or efficacy, according to data from post-approval post-hoc analysis.